Company intelligence / Profile preview

Millendo Therapeutics SAS

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Other

Overview

Millendo Therapeutics SAS was established after Millendo Therapeutics, Inc. acquired Alizé Pharma SAS in 2017, creating a transatlantic biotech focused on endocrine diseases. The company advanced livoletide, a peptide for Prader-Willi syndrome, into a pivotal Phase 2b/3 trial, and nevanimibe, a small molecule, into Phase 2b for congenital adrenal hyperplasia and Cushing’s syndrome. While initial trial results showed promising efficacy and tolerability, all key clinical programs have since been discontinued. The company no longer appears to be actively developing new therapies.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: PeptideSmall molecule
Industry: Biotech

Partnerships

Collaboration with leading European endocrinologists (founders of Alizé Pharma SAS)

Beyond the preview

Go deeper on Millendo Therapeutics SAS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Millendo Therapeutics SAS.

Explore the full profile